Abstract
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with SCLC relapsing within 3 months of cytotoxic therapy received paclitaxel 175 mg m(-2) intravenously over 3 h every 3 weeks. The dose of paclitaxel was adjusted to the toxicity encountered in the previous cycle. Of 24 patients entered into the study, 24 and 21 were assessable for response and toxicity respectively. There were two early deaths and two toxic deaths. No complete and seven partial responses (29%) (95%CI 12-51%) were observed and five patients had disease stabilization. The median survival (n = 21) was 100 days. Life-threatening toxicity occurred in four patients; in others (non)-haematological toxicity was manageable. Paclitaxel is active in drug-resistant SCLC. Further investigation in combination with other active agents in this poor prognosis group is appropriate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smit, E., Fokkema, E., Biesma, B. et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77, 347–351 (1998). https://doi.org/10.1038/bjc.1998.54
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.54
This article is cited by
-
Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
Radiation Oncology (2021)
-
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
British Journal of Cancer (2020)
-
Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib
Journal of Cancer Research and Clinical Oncology (2020)
-
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial
Clinical and Translational Oncology (2018)
-
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)
Cancer Chemotherapy and Pharmacology (2014)